Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

WRIGHT MEDICAL GROUP N.V.

(WMGI)
SummaryChartsNewsRatingsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Wright Medical N : 2019 Annual Report

09/18/2020 | 05:25pm EDT

2019 annual report

AP-014156A_01-Sep-2020_Annual Report 2019.indd 2

9/2/2020 1:23:41 PM

Corporate Overview

Wright Medical Group N.V. is a global medical device company focused on Extremities and Biologics. The company is committed

to delivering innovative, value-added solutions improving the quality of life for patients worldwide. We are a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics.

Our ordinary shares are traded on the Nasdaq Global Select Market under the symbol "WMGI".

Our Vision

Your First Choice in Extremities and Biologics

Our Mission

We focus on Extremities and Biologics.

Through our team of passionate and dedicated people, we deliver innovative, value-added solutions improving quality of life for patients worldwide.

We are committed to compliance and the highest standards of ethical conduct.

Our Values

  • Think Customer
  • Enable Change
  • Alignment
  • eMpowerment
  • Sustainability

20

19

AP-014156A_01-Sep-2020_Annual Report 2019.indd 3

9/2/2020 1:23:43 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

(Mark One)

  • ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 29, 2019 or

  • TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

to

Commission file number: 001-35065

WRIGHT MEDICAL GROUP N.V.

(Exact name of registrant as specified in its charter)

The Netherlands

98-0509600

(State or other jurisdiction

(I.R.S. Employer

of incorporation or organization)

Identification No.)

Prins Bernhardplein 200

None

1097 JB Amsterdam, The Netherlands

(Zip Code)

(Address of principal executive offices)

Registrant's telephone number, including area code: (+31) 20 521 4777

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Ordinary shares, par value €0.03 per share

WMGI

Nasdaq Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to

such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

The aggregate market value of the ordinary shares held by non-affiliates of the registrant on June 30, 2019 was $3.7 billion based on the closing sale price of the ordinary shares on that date, as reported by the Nasdaq Global Select Market. For purposes of the foregoing calculation only, the registrant has assumed that all executive officers and directors of the registrant, and their affiliated entities, are affiliates.

As of February 20, 2020, there were 128,733,780 ordinary shares outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Part III of this Annual Report on Form 10-K incorporates by reference certain portions of the registrant's definitive proxy statement for its Extraordinary General Meeting of Shareholders ("Proxy Statement") anticipated to be filed with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year covered by this report. Except as expressly incorporated by reference, the registrant's Proxy Statement shall not be deemed to be part of this report.

WRIGHT MEDICAL GROUP N.V.

ANNUAL REPORT ON FORM 10-K

Table of Contents

PART I ............................................................................................................................................................................................

4

Item 1.

Business.................................................................................................................................................................

4

Item 1A.

Risk Factors..........................................................................................................................................................

17

Item 1B.

Unresolved Staff Comments.................................................................................................................................

42

Item 2.

Properties..............................................................................................................................................................

42

Item 3.

Legal Proceedings. ...............................................................................................................................................

43

PART II..........................................................................................................................................................................................

46

Item 5.

Market for Registrant's Common Equity, Related Shareholder Matters and Issuer Purchases of Equity

Securities. .............................................................................................................................................................

46

Item 6.

Selected Financial Data. .......................................................................................................................................

48

Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations. ..............................

49

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk. .............................................................................

70

Item 8.

Financial Statements and Supplementary Data. ...................................................................................................

75

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. ............................

124

Item 9A.

Controls and Procedures.....................................................................................................................................

124

Item 9B.

Other Information...............................................................................................................................................

124

PART III ......................................................................................................................................................................................

125

Item 10.

Directors, Executive Officers and Corporate Governance..................................................................................

125

Item 11.

Executive Compensation. ...................................................................................................................................

125

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. ..........

125

Item 13.

Certain Relationships and Related Transactions, and Director Independence....................................................

125

Item 14.

Exhibits, Financial Statement Schedules. ...........................................................................................................

125

PART IV ......................................................................................................................................................................................

126

Item 15.

Exhibits, Financial Statement Schedules. ...........................................................................................................

126

Item 16.

Form 10-K Summary. .........................................................................................................................................

135

i

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Wright Medical Group NV published this content on 18 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 September 2020 21:24:06 UTC


ę Publicnow 2020
All news about WRIGHT MEDICAL GROUP N.V.
2020'Boris the betrayer' has swindled us over Brexit, England's fishermen say
RE
2020STRYKERá : FTC Approves Conditions on Stryker's Acquisition of Wright Medical
DJ
2020Wright Medical Announces Fundamental Change With Respect to the 2.25% Cash Co..
GL
2020UK's CMA Says Stryker's Divestments Resolve Concerns on Wright Medical Acquis..
DJ
2020STRYKERá : FTC Says Stryker, Wright Medical Must Divest Assets as Part of Acquis..
DJ
2020WRIGHT MEDICAL Ná : Extension Notice of the First Step Merger 35.7 KB
PU
2020WRIGHT MEDICAL Ná : Proxy Statement for 2020 Annual General Meeting of Wright Me..
PU
2020WRIGHT MEDICAL Ná : 2019 Annual Report
PU
2020STRYKERá : UK CMA Seeks Comments About Stryker, Wright Medical Offer Before Maki..
DJ
2020Wright Medical Group N.V. Announces Update to Medicare Transitional Device Pa..
GL
More news
Chart WRIGHT MEDICAL GROUP N.V.
Duration : Period :
Wright Medical Group N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
NameTitle
Spencer S. Stiles President
Lance A. Berry EVP, Chief Financial & Operations Officer
Jonathan Wesley Porter Chief Compliance Officer & Senior Vice President
Robert P. Burrows Senior Vice President-Supply Chain
Kevin D. Cordell Chief Global Commercial Officer & Executive VP
Sector and Competitors